The Origin of Xanthine Oxidase and Its Metabolite, Uric Acid, in Preeclamptic Pregnant Women - A Pilot Study
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Barzilai Medical Center
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Uric Acid
Study Overview
Brief Summary
Findings regarding the presence of xanthine oxidase and uric acid in different blood locations is important in preeclamptic women. We aim to detecting Xanthine oxidase and uric acid levels in both umbilical cord artery and vein as well as maternal blood (3 "locations") in pregnant women with and without diagnosis of preeclampsia. The study population will be divided into groups matching the three "locations" in order to describe and compare outcome levels.
Detailed Description
Significance - findings regarding the presence of xanthine oxidase and uric acid in different blood locations may provide a scientific basis for understanding the source of them in preeclamptic women. Aim - detecting Xanthine oxidase and uric acid levels in both umbilical cord artery and vein as well as maternal blood (3 "locations"). Methods - samples will be collected from pregnant women with and without diagnosis of preeclampsia with blood uric acid > 6 mg/dL. Than the study population will be divided into groups matching the three "locations". The investigators will describe and compare outcome levels (including Xanthine oxidase, uric acid).
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 20 Years to 55 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •preeclampsia and none-preeclampsia diagnosed pregnant women.
Exclusion Criteria
- •Known or reported kidney disease.
Outcomes
Primary Outcomes
Uric Acid
Time Frame: through study completion, an average of 1 year
mg/dL
Secondary Outcomes
No secondary outcomes reported
Investigators
Simon Shanhav
Dr Simon Shenhav, head of High Risk Pregnancy Unit
Barzilai Medical Center